June 8, 2022 -- Contract research, development, and manufacturing organization Curia has adopted Berkeley Lights’ platform to accelerate and expand its antibody-based drug discovery capabilities.
The Beacon Optofluidic system and workflow from Berkeley Lights provides a seamless and comprehensive portfolio of state-of-the-art technologies for rapid progression of client antibody programs, addressing the earliest stage of discovery, through maturation and development, to manufacture new drugs and final drug products under good manufacturing practice (GMP).
"Speed counts in drug discovery, so the ability to conduct high-throughput, single-cell experiments is a game changer, enabling abundant and diverse leads," said Christopher Conway, president of R&D at Curia. "Advanced technologies such as the Berkeley Lights platform are revolutionizing antibody discovery, tackling key pain points that confront innovators, such as long timelines and limited number of sequences."
Copyright © 2022 scienceboard.net